... disease and other dementias), Parkinson’s disease and Parkinsonism, and multiple sclerosis in the Spanish-Portuguese cross-border border region in 2020. It includes Bragança and Guarda Districts (Portugal) and Salamanca (Castilla y León, Spain). Results: Neurodegenerative diseases accounted for 1.85...

...Antonella Conte; Carlos Vila Silván Background: Sativex (USAN: nabiximols [NAB]) oromucosal spray is indicated for treatment of multiple sclerosis (MS) patients with moderate to severe spasticity and inadequate response to other antispasticity medications who demonstrate clinically significant...

... with multiple sclerosis. Methods: Thirty participants with multiple sclerosis (Expanded Disability Status Scale ≤6) were randomized into either an exercise and control groups. The exercise group performed 8-weeks of endurance, resistance, and balance exercise training. Serum concentrations of IL-6, CRP, and IL...

...María Sol Fittipaldi-Márquez; Álvaro Javier Cruz-Gómez; Carla Sanchis-Segura; Antonio Belenguer; César Ávila; Cristina Forn Background: Reduced information-processing speed (IPS) is a primary cognitive deficit of multiple sclerosis (MS) patients. The neural efficiency hypothesis describes...

...: We found 3 female patients (37, 69 and 68 years of age) with a diagnosis of SCH. Two of them presented with concomitant, relatively rare disabling neurological diseases, namely amyotrophic lateral sclerosis and multiple sclerosis. The third patient underwent surgery and gradually recovered over 6...

... as an experimental treatment of multiple sclerosis for more than 15 years. Here, we summarise our clinical and laboratory findings, describing how this prototypical ‘bench to bedside’ therapy continues to inform basic science, revealing aspects of the pathogenesis of multiple sclerosis and autoimmunity. 14 12...

...E. Taoufik; V. Tseveleki; M. Euagelidou; M. Emmanouil; A. Voulgari-Kokota; S. Haralambous; L. Probert Multiple sclerosis (MS) is a progressive, presumably autoimmune, degenerative disease of the central nervous system (CNS). The mechanisms which trigger the disease are unknown, but the pathology...

...Britta Engelhardt; Ludwig Kappos In 1992, it was shown that monoclonal antibodies blocking α 4 -integrins prevent the development of experimental autoimmune encephalomyelitis, an animal model for multiple sclerosis (MS). As α 4 β 1 -integrin was demonstrated to mediate the attachment of immune...

... ago for the prevention of allotransplant rejection and adult T cell leukemia. Following promising observations in uveitis, daclizumab has been tested in a number of small clinical trials in multiple sclerosis based on the rationale that blocking CD25 would prevent the expansion of autoreactive T...